http://www.nasdaq.com/article/will-axsome-therapeutics-axsm-…
.."as AXSM has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company.."
Schaun wa mal
|
http://www.nasdaq.com/article/will-axsome-therapeutics-axsm-… .."as AXSM has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company.." Schaun wa mal |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | schalkimnacken (22.06.17 12:18:44) |
| Beitrag: | 98 von 268 (ID:55184786) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |